Intellipharmaceutics International Inc. (IPCIF)
USD 0.15
(N/A%)
USD 0.15
(N/A%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.85 Million USD | 0.0% |
| 2022 | -2.85 Million USD | 31.69% |
| 2021 | -4.17 Million USD | 10.8% |
| 2020 | -4.67 Million USD | 64.89% |
| 2019 | -13.32 Million USD | -61.22% |
| 2018 | -8.26 Million USD | 16.09% |
| 2017 | -9.85 Million USD | -38.49% |
| 2016 | -7.11 Million USD | -101.36% |
| 2015 | -3.53 Million USD | 48.19% |
| 2014 | -6.81 Million USD | 32.6% |
| 2013 | -10.11 Million USD | -30.09% |
| 2012 | -7.77 Million USD | -28.49% |
| 2011 | -6.05 Million USD | 0.0% |
| 2009 | -13.6 Million USD | 48.55% |
| 2008 | -26.43 Million USD | 44.6% |
| 2007 | -47.72 Million USD | 40.67% |
| 2006 | -80.44 Million USD | -25.79% |
| 2005 | -63.95 Million USD | -150.85% |
| 2004 | -25.49 Million USD | -94.77% |
| 2003 | -13.08 Million USD | -25.13% |
| 2002 | -10.46 Million USD | -42.59% |
| 2001 | -7.33 Million USD | -38.34% |
| 2000 | -5.3 Million USD | -13.02% |
| 1999 | -4.69 Million USD | 13.28% |
| 1998 | -5.41 Million USD | -58.51% |
| 1997 | -3.41 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -301.4 Thousand USD | 34.42% |
| 2024 Q3 | -1.78 Million USD | -5600.44% |
| 2024 Q2 | -31.35 Thousand USD | 89.6% |
| 2023 FY | -2.85 Million USD | 0.0% |
| 2023 Q3 | -366.18 Thousand USD | 70.75% |
| 2023 Q4 | -459.57 Thousand USD | -25.51% |
| 2023 Q1 | -772.91 Thousand USD | 44.69% |
| 2023 Q2 | -1.25 Million USD | -61.96% |
| 2022 FY | -2.85 Million USD | 31.69% |
| 2022 Q1 | -784.91 Thousand USD | 46.33% |
| 2022 Q2 | -906.85 Thousand USD | -15.54% |
| 2022 Q3 | -1.08 Million USD | -19.51% |
| 2022 Q4 | -1.39 Million USD | -28.94% |
| 2021 Q2 | -890.24 Thousand USD | 25.58% |
| 2021 Q4 | -1.46 Million USD | -29.48% |
| 2021 Q1 | -1.19 Million USD | 6.33% |
| 2021 FY | -4.17 Million USD | 10.8% |
| 2021 Q3 | -1.12 Million USD | -26.87% |
| 2020 Q2 | -2.04 Million USD | 35.22% |
| 2020 Q3 | -1.36 Million USD | 33.43% |
| 2020 Q4 | -1.27 Million USD | 6.12% |
| 2020 FY | -4.67 Million USD | 64.89% |
| 2020 Q1 | -3.15 Million USD | 10.53% |
| 2019 FY | -13.32 Million USD | -61.22% |
| 2019 Q4 | -3.52 Million USD | 9.68% |
| 2019 Q1 | -3.09 Million USD | -34.52% |
| 2019 Q3 | -3.9 Million USD | -39.13% |
| 2019 Q2 | -2.8 Million USD | 9.23% |
| 2018 FY | -8.26 Million USD | 16.09% |
| 2018 Q1 | -1.84 Million USD | 51.6% |
| 2018 Q3 | -2.36 Million USD | -35.25% |
| 2018 Q2 | -1.75 Million USD | 5.3% |
| 2018 Q4 | -2.29 Million USD | 2.96% |
| 2017 Q1 | -2.09 Million USD | 33.27% |
| 2017 Q2 | -1.9 Million USD | 9.0% |
| 2017 Q3 | -2.03 Million USD | -6.57% |
| 2017 Q4 | -3.81 Million USD | -88.07% |
| 2017 FY | -9.85 Million USD | -38.49% |
| 2016 FY | -7.11 Million USD | -101.36% |
| 2016 Q1 | -847.26 Thousand USD | 24.87% |
| 2016 Q4 | -3.13 Million USD | -79.35% |
| 2016 Q2 | -1.37 Million USD | -62.64% |
| 2016 Q3 | -1.74 Million USD | -26.98% |
| 2015 Q4 | -1.12 Million USD | 28.84% |
| 2015 FY | -3.53 Million USD | 48.19% |
| 2015 Q3 | -1.58 Million USD | 48.31% |
| 2015 Q2 | -3.06 Million USD | -236.54% |
| 2015 Q1 | 2.24 Million USD | 311.03% |
| 2014 FY | -6.81 Million USD | 32.6% |
| 2014 Q1 | -2.26 Million USD | 21.14% |
| 2014 Q2 | -1.78 Million USD | 21.1% |
| 2014 Q3 | -1.7 Million USD | 4.62% |
| 2014 Q4 | -1.06 Million USD | 37.56% |
| 2013 Q2 | -1.99 Million USD | 35.72% |
| 2013 Q4 | -2.87 Million USD | -34.11% |
| 2013 Q3 | -2.14 Million USD | -7.18% |
| 2013 Q1 | -3.1 Million USD | -38.62% |
| 2013 FY | -10.11 Million USD | -30.09% |
| 2012 Q4 | -2.24 Million USD | -64.45% |
| 2012 Q1 | -1.77 Million USD | 13.85% |
| 2012 FY | -7.77 Million USD | -28.49% |
| 2012 Q3 | -1.36 Million USD | 43.22% |
| 2012 Q2 | -2.4 Million USD | -35.6% |
| 2011 Q4 | -2.05 Million USD | 0.82% |
| 2011 Q2 | -468.67 Thousand USD | 67.81% |
| 2011 Q1 | -1.45 Million USD | 0.0% |
| 2011 FY | -6.05 Million USD | 0.0% |
| 2011 Q3 | -2.07 Million USD | -342.17% |
| 2010 Q3 | -1.06 Million USD | 17.59% |
| 2010 Q2 | -1.28 Million USD | 33.4% |
| 2010 Q1 | -1.93 Million USD | -254.56% |
| 2009 FY | -13.6 Million USD | 48.55% |
| 2009 Q4 | 1.24 Million USD | 149.83% |
| 2009 Q3 | -2.5 Million USD | 67.99% |
| 2009 Q2 | -7.83 Million USD | -40.62% |
| 2009 Q1 | -5.57 Million USD | 2.21% |
| 2008 FY | -26.43 Million USD | 44.6% |
| 2008 Q4 | -5.69 Million USD | -5.25% |
| 2008 Q1 | -5.77 Million USD | -278.16% |
| 2008 Q3 | -5.41 Million USD | 32.94% |
| 2008 Q2 | -8.07 Million USD | -39.82% |
| 2007 Q3 | -10.08 Million USD | 36.83% |
| 2007 Q1 | -14.85 Million USD | 28.95% |
| 2007 FY | -47.72 Million USD | 40.67% |
| 2007 Q4 | 3.23 Million USD | 132.13% |
| 2007 Q2 | -15.96 Million USD | -7.45% |
| 2006 Q1 | -16.46 Million USD | 41.74% |
| 2006 Q4 | -20.91 Million USD | -0.67% |
| 2006 Q3 | -20.77 Million USD | -1.37% |
| 2006 Q2 | -20.49 Million USD | -24.42% |
| 2006 FY | -80.44 Million USD | -25.79% |
| 2005 Q1 | -9.28 Million USD | 18.74% |
| 2005 Q3 | -15.27 Million USD | -44.44% |
| 2005 FY | -63.95 Million USD | -150.85% |
| 2005 Q2 | -10.57 Million USD | -13.94% |
| 2005 Q4 | -28.27 Million USD | -85.1% |
| 2004 Q4 | -11.42 Million USD | -156.27% |
| 2004 Q1 | -3.87 Million USD | -1.51% |
| 2004 Q2 | -5.51 Million USD | -42.38% |
| 2004 Q3 | -4.45 Million USD | 19.17% |
| 2004 FY | -25.49 Million USD | -94.77% |
| 2003 Q2 | -3.05 Million USD | 5.84% |
| 2003 Q1 | -3.24 Million USD | -18.53% |
| 2003 Q4 | -3.81 Million USD | -29.67% |
| 2003 FY | -13.08 Million USD | -25.13% |
| 2003 Q3 | -2.94 Million USD | 3.73% |
| 2002 Q1 | -2.19 Million USD | -7.14% |
| 2002 FY | -10.46 Million USD | -42.59% |
| 2002 Q3 | -2.66 Million USD | 7.84% |
| 2002 Q4 | -2.73 Million USD | -2.54% |
| 2002 Q2 | -2.89 Million USD | -31.98% |
| 2001 FY | -7.33 Million USD | -38.34% |
| 2001 Q4 | -2.04 Million USD | 1.85% |
| 2001 Q3 | -2.08 Million USD | -23.82% |
| 2001 Q2 | -1.68 Million USD | -11.51% |
| 2001 Q1 | -1.51 Million USD | 11.49% |
| 2000 Q1 | -900.96 Thousand USD | 43.4% |
| 2000 Q3 | -1.29 Million USD | -8.49% |
| 2000 FY | -5.3 Million USD | -13.02% |
| 2000 Q4 | -1.7 Million USD | -31.56% |
| 2000 Q2 | -1.19 Million USD | -32.82% |
| 1999 Q1 | -1.19 Million USD | 21.59% |
| 1999 Q2 | -1.02 Million USD | 13.79% |
| 1999 Q4 | -1.59 Million USD | -57.24% |
| 1999 Q3 | -1.01 Million USD | 1.69% |
| 1999 FY | -4.69 Million USD | 13.28% |
| 1998 Q2 | -1.3 Million USD | -27.68% |
| 1998 Q3 | -1.36 Million USD | -4.73% |
| 1998 Q1 | -1.02 Million USD | 0.0% |
| 1998 FY | -5.41 Million USD | -58.51% |
| 1998 Q4 | -1.52 Million USD | -11.37% |
| 1997 FY | -3.41 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Evofem Biosciences, Inc. | -17.84 Million USD | 84.028% |
| Neon Bloom, Inc. | -389.57 Thousand USD | -631.706% |
| Nascent Biotech, Inc. | -2.22 Million USD | -27.832% |
| ProtoKinetix, Incorporated | -415.47 Thousand USD | -586.077% |
| Qrons Inc. | -643.67 Thousand USD | -342.847% |
| Rebus Holdings, Inc. | -664 Thousand USD | -329.293% |
| Skye Bioscience, Inc. | -13.67 Million USD | 79.15% |
| Santhera Pharmaceuticals Holding AG | 81.85 Million USD | 103.483% |
| Adynxx, Inc. | - USD | Infinity% |
| Northwest Biotherapeutics, Inc. | -55.5 Million USD | 94.865% |
| Acro Biomedical Co., Ltd. | -15.86 Million USD | 82.038% |
| Arch Therapeutics, Inc. | -5.04 Million USD | 43.493% |
| Burzynski Research Institute, Inc. | -1.33 Million USD | -113.452% |
| Eiger BioPharmaceuticals, Inc. | -71.78 Million USD | 96.029% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 157.998% |
| Institute of Biomedical Research Corp. | -261.72 Thousand USD | -989.119% |
| SQZ Biotechnologies Company | -75.82 Million USD | 96.241% |
| Propanc Biopharma, Inc. | -1.53 Million USD | -85.574% |
| Mesoblast Limited | -84.14 Million USD | 96.612% |
| Marizyme, Inc. | -34.08 Million USD | 91.637% |
| Genus plc | 6.4 Million USD | 144.539% |
| VioQuest Pharmaceuticals, Inc. | 9.74 Million USD | 129.259% |
| Pharming Group N.V. | -4.87 Million USD | 41.583% |
| Therapeutic Solutions International, Inc. | -1.98 Million USD | -43.495% |
| CNBX Pharmaceuticals Inc. | -931.38 Thousand USD | -206.052% |
| Nymox Pharmaceutical Corporation | -8.35 Million USD | 65.862% |
| ContraFect Corporation | -56.88 Million USD | 94.989% |
| PsyBio Therapeutics Corp. | -4.55 Million USD | 37.416% |
| Sienna Biopharmaceuticals, Inc. | - USD | Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | -1.4 Million USD | -103.318% |
| IMV Inc. | -38.67 Million USD | 92.629% |
| AXIM Biotechnologies, Inc. | -2.75 Million USD | -3.623% |
| MultiCell Technologies, Inc. | -722.81 USD | -394264.632% |
| ONE Bio Corp. | 13.68 Million USD | 120.835% |
| Accustem Sciences Inc. | -3.74 Million USD | 23.914% |
| RVL Pharmaceuticals plc | -58.99 Million USD | 95.168% |
| Arno Therapeutics, Inc. | - USD | Infinity% |
| EV Biologics, Inc. | -483.06 Thousand USD | -490.091% |
| Q BioMed Inc. | -3.44 Million USD | 17.271% |
| Emmaus Life Sciences, Inc. | 3.54 Million USD | 180.523% |
| Mosaic ImmunoEngineering Inc. | -2.62 Million USD | -8.487% |
| Biomind Labs Inc. | -1 Million USD | -182.339% |
| American Oriental Bioengineering, Inc. | -54.97 Million USD | 94.815% |
| Provectus Biopharmaceuticals, Inc. | -2.9 Million USD | 1.749% |
| TetraLogic Pharmaceuticals Corporation | - USD | Infinity% |
| Oncotelic Therapeutics, Inc. | -6.64 Million USD | 57.122% |
| GlobeStar Therapeutics Corporation | -1.86 Million USD | -52.894% |
| THC Farmaceuticals, Inc. | -29.95 Thousand USD | -9416.917% |
| Curative Biotechnology, Inc. | -1.93 Million USD | -47.495% |
| GB Sciences, Inc. | -1.42 Million USD | -100.668% |
| Alpha Cognition Inc. | -9.7 Million USD | 70.63% |
| HST Global, Inc. | -140.9 Thousand USD | -1922.97% |
| CSL Limited | 3.7 Billion USD | 100.077% |
| Wesana Health Holdings Inc. | -1.12 Million USD | -153.4% |
| Halberd Corporation | -75.05 Thousand USD | -3698.144% |
| Enzolytics Inc. | -2.14 Million USD | -32.656% |
| Agentix Corp. | -1.37 Million USD | -107.8% |
| Resverlogix Corp. | -12.74 Million USD | 77.641% |
| Nuo Therapeutics, Inc. | -3.16 Million USD | 10.03% |
| MetaStat, Inc. | - USD | Infinity% |
| argenx SE | -425.04 Million USD | 99.329% |
| Enzon Pharmaceuticals, Inc. | -1.04 Million USD | -173.037% |
| Endonovo Therapeutics, Inc. | -2.91 Million USD | 2.361% |
| RespireRx Pharmaceuticals Inc. | -1.57 Million USD | -80.486% |
| GeneThera, Inc. | - USD | Infinity% |
| Inhibitor Therapeutics, Inc. | -3.4 Million USD | 16.284% |
| AVAX Technologies, Inc. | 6.69 Million USD | 142.59% |
| Zenith Capital Corp. | -8.94 Million USD | 68.126% |
| Genscript Biotech Corporation | -415.79 Million USD | 99.314% |
| Ember Therapeutics, Inc. | -17.42 Thousand USD | -16262.476% |
| Anthera Pharmaceuticals, Inc. | - USD | Infinity% |
| Sigyn Therapeutics, Inc. | -2.45 Million USD | -16.095% |
| WPD Pharmaceuticals Inc. | -171.5 Thousand USD | -1562.011% |
| Cotinga Pharmaceuticals Inc. | -2 Million USD | -42.187% |
| Kadimastem Ltd | -3.04 Million USD | 6.241% |
| Helix BioMedix, Inc. | -984.05 Thousand USD | -189.67% |
| VitaSpring Biomedical Co. Ltd. | - USD | Infinity% |
| Capstone Therapeutics Corp. | -1.25 Million USD | -126.951% |
| BioStem Technologies, Inc. | -7.77 Million USD | 63.356% |
| Oncology Pharma Inc. | - USD | Infinity% |
| Reve Technologies, Inc. | -181.48 Thousand USD | -1470.657% |
| LadRx Corporation | -3.82 Million USD | 25.45% |
| Cell Source, Inc. | -4.32 Million USD | 34.098% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -314.951% |
| Regen BioPharma, Inc. | -686.95 Thousand USD | -314.951% |
| NovAccess Global Inc. | -2.46 Million USD | -15.557% |
| Affymax, Inc. | -15.04 Million USD | 81.055% |
| Itoco Inc. | -919.14 Thousand USD | -210.128% |
| Rasna Therapeutics, Inc. | -4.23 Million USD | 32.746% |
| Pathfinder Cell Therapy, Inc. | -1.11 Million USD | -154.737% |
| Mobile Lads Corp. | -554.55 Thousand USD | -414.022% |
| CytoDyn Inc. | -18.05 Million USD | 84.215% |
| Claritas Pharmaceuticals, Inc. | - USD | Infinity% |
| NDT Pharmaceuticals Inc. | -25.17 Thousand USD | -11225.018% |
| NanoSphere Health Sciences Inc. | -220.07 Thousand USD | -1195.226% |
| Alseres Pharmaceuticals, Inc. | -564.72 Thousand USD | -404.762% |
| SYBLEU INC | -149.18 Thousand USD | -1810.784% |
| Advanced Proteome Therapeutics Corporation | - USD | Infinity% |
| ImmunoCellular Therapeutics, Ltd. | -1.81 Million USD | -56.939% |
| International Stem Cell Corporation | -663 Thousand USD | -329.941% |
| Bioxytran, Inc. | -3.82 Million USD | 25.382% |
| GlobeImmune, Inc. | - USD | Infinity% |
| Predictive Technology Group, Inc. | - USD | Infinity% |
| ProText Mobility, Inc. | -52.64 Thousand USD | -5315.097% |
| Cardax, Inc. | - USD | Infinity% |
| VG Life Sciences Inc. | -20.34 Thousand USD | -13914.292% |
| Kaleido Biosciences, Inc. | - USD | Infinity% |
| Advaxis, Inc. | -36.26 Million USD | 92.14% |
| Adhera Therapeutics, Inc. | -1.61 Million USD | -76.175% |
| RenovaCare, Inc. | - USD | Infinity% |
| Regnum Corp. | -735.83 Thousand USD | -287.384% |
| Innovation Pharmaceuticals Inc. | -3.11 Million USD | 8.373% |
| Neutra Corp. | -229.48 Thousand USD | -1142.127% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 83.748% |
| PureTech Health plc | -146.19 Million USD | 98.05% |
| Coeptis Therapeutics, Inc. | -21.49 Million USD | 86.736% |
| IXICO plc | -1.43 Million USD | -98.365% |
| IntelGenx Technologies Corp. | -9.49 Million USD | 69.966% |
| Gelesis Holdings, Inc. | -121.8 Million USD | 97.66% |
| CSL Limited | 3.81 Billion USD | 100.075% |
| Cellectis S.A. | -108.85 Million USD | 97.381% |